{
    "eid": "2-s2.0-85166379446",
    "title": "Development and characterization of mouse anti-canine PD-L1 monoclonal antibodies and their expression in canine tumors by immunohistochemistry in vitro",
    "cover-date": "2023-01-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Veterinary (all)",
            "@code": "3400",
            "@abbrev": "VETE"
        }
    ],
    "keywords": [
        "anti-canine PD-L1 antibody",
        "canine PD-L1",
        "Dog",
        "immune checkpoint inhibitor"
    ],
    "authors": [
        "Sirintra Sirivisoot",
        "Chatikorn Boonkrai",
        "Tossapon Wongtangprasert",
        "Tanapati Phakham",
        "Phijitra Muanwein",
        "Trairak Pisitkun",
        "Chenphop Sawangmake",
        "Araya Radtanakatikanon",
        "Anudep Rungsipipat"
    ],
    "citedby-count": 0,
    "ref-count": 28,
    "ref-list": [
        "Quantification and prognostic value of programmed cell death ligand-1 expression in dogs with diffuse large B-cell lymphoma",
        "Prognostic value of PD-L1, PD-1 and CD8A in canine diffuse large B-cell lymphoma detected by RNAscope",
        "Increased programmed death ligand (PD-L1) and cytotoxic T-lymphocyte antigen-4 (CTLA-4) expression is associated with metastasis and poor prognosis in malignant canine mammary gland tumours",
        "Canine osteosarcoma checkpoint expression correlates with metastasis and T-cell infiltrate",
        "Development of canine PD-1/PD-L1 specific monoclonal antibodies and amplification of canine T cell function",
        "Immune regulation of canine tumour and macrophage PD-L1 expression",
        "A pilot clinical study of the therapeutic antibody against canine PD-1 for advanced spontaneous cancers in dogs",
        "The role of PD-1 in acute and chronic infection",
        "Programmed death ligand 1 is expressed in canine B cell lymphoma and downregulated by MEK inhibitors",
        "PD-L2 is a second ligand for PD-1 and inhibits T cell activation",
        "Expression of PD-L1 on canine tumor cells and enhancement of IFN-gamma production from tumor-infiltrating cells by PD-L1 blockade",
        "PD-L1 immunohistochemistry for canine cancers and clinical benefit of anti-PD-L1 antibody in dogs with pulmonary metastatic oral malignant melanoma",
        "Immunohistochemical analysis of PD-L1 expression in canine malignant cancers and PD-1 expression on lymphocytes in canine oral melanoma",
        "A canine chimeric monoclonal antibody targeting PD-L1 and its clinical efficacy in canine oral malignant melanoma or undifferentiated sarcoma",
        "Development of monoclonal antibodies targeting canine PD-L1 and PD-1 and their clinical relevance in canine apocrine gland anal sac adenocarcinoma",
        "PD-L1 expression in triple-negative breast cancer",
        "The future of cancer immunotherapy: microenvironment-targeting combinations",
        "Development and characterization of monoclonal antibodies against canine PD-1 and PD-L1",
        "Cross-Reactivity and Functionality of Approved Human Immune Checkpoint Blockers in Dogs",
        "Highly efficient hybridoma generation and screening strategy for anti-PD-1 monoclonal antibody development",
        "Evaluation of PD-1 and PD-L1 expression in canine urothelial carcinoma cell lines",
        "Immune-related gene expression profiling after PD-1 blockade in non-small cell lung carcinoma, head and neck squamous cell carcinoma, and melanoma",
        "Programmed cell death ligand 1 expression in canine cancer",
        "PD-1, PD-L1, and PD-L2 gene expression and tumor infiltrating lymphocytes in canine melanoma",
        "Regulation and function of the PD-L1 checkpoint",
        "Immune evasion via PD-1/PD-L1 on NK cells and monocyte/macrophages is more prominent in Hodgkin lymphoma than DLBCL",
        "Immune evasion in cancer: mechanistic basis and therapeutic strategies",
        "Expression of programmed death 1 ligands by murine T cells and APC"
    ],
    "affiliation": [
        {
            "affiliation-city": "Bangkok",
            "@id": "60028190",
            "affilname": "Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60199584",
            "affilname": "Chulalongkorn Cancer Immunotherapy Excellence Center",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60199584",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60002620",
            "affilname": "Faculty of Medicine, Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002620",
            "affiliation-country": "Thailand"
        }
    ],
    "funding": [
        "Center of Excellence for Companion Animal Cancer",
        "Department of Veterinary Surgery",
        "Chulalongkorn University",
        "Thailand Science Research and Innovation Fund",
        "Faculty of Veterinary Science, Chulalongkorn University"
    ]
}